Cancer drugs, sold under other people's labels — and five years of trying to become more than the ingredient supplier. Three businesses now: APIs at 47% of June-quarter revenue, finished formulations at 42%, and biologics at 11%, with oncology accounting for 46% of API sales in FY26. It sells 58 APIs and 43 formulation products through partners into more than 50 countries, from more than ten regulatory-approved manufacturing and research sites, and has filed 283 drug master files. Whether it is good at it depends on which year you ask. Revenue was ₹1,535 crore in FY26, up 19.9%, with profit of ₹243 crore against ₹78 crore the year before, and the June quarter was the best in its history at ₹469 crore. The cleaner measure is the balance sheet: net debt was 6.7 times EBITDA in FY23 and 1.3 times in the June quarter, and India Ratings upgraded the company from A+ to AA− in July 2026.
On pipeline, yes. On revenue, not yet. Shilpa has more than 25 contract programmes running across the group with over 20 customers, three of them late-stage and due to enter commercial supply in FY28 — but management confirmed on the August call that exactly one product is commercial on the CDMO side today, and CDMO was 6% of FY26 revenue. Capacity utilisation is not disclosed; asked directly about the Bangalore, Jadcherla and Dharwad plants, management referred the question to its investor relations head. This is a pipeline you are asked to take on trust, and the company's own framing agrees with that reading: the reinvesting is largely behind us, the harvesting is ahead of us.
No, though it took three years of work to be able to say so. It owes ₹660 crore and holds ₹45 crore of cash, so repaying everything would leave ₹615 crore against ₹2,591 crore of shareholders' money — a debt-to-equity of 0.25. What changed in FY26 was the shape of the debt rather than its size: Shilpa repaid most of its high-interest debentures and turned the rest into bank loans, and interest cover went from 4.2 times to 7.4. Repayments are ₹60 crore a year in FY27, FY28 and FY29. The figure that is not in the debt number is ₹884 crore of unfinished assets — ₹431 crore of plants still under construction and ₹453 crore of product development capitalised rather than expensed. That is the investment case and the risk in the same line.
The June quarter was the best in the company's history — ₹469 crore of revenue, up 43%, at a 30% EBITDA margin — and it came from every division at once. Margins widened even as gross margin fell five points, operating cash flow more than doubled to ₹342 crore in FY26, and the return on capital rose from 6.9% to 11.4%. The unfinished part shows in the same accounts: customers still take 123 days to pay, and the return on capital remains below what the better-regarded contract manufacturers earn.
Sales steadily, profit spectacularly — because profit started from almost nothing. Revenue was ₹1,535 crore in FY26, up 19.9% from ₹1,281 crore, and has compounded at 13.6% a year over three years and 11.3% over five. Profit was ₹243 crore against ₹78 crore, up 211%. That multiple is real but it flatters: Shilpa lost money in FY23 and earned ₹1.84 a share in FY24, so the comparison is against a floor rather than a trend. The June quarter carried it forward — ₹469 crore of revenue, up 43%, and ₹101 crore of profit, up 115%.
Built, with small stakes bought on the side. Gross block went from ₹1,997 crore to ₹2,281 crore in FY26 on net capex of ₹361 crore, with a further ₹114 crore spent in the June quarter, funded, management says, mainly from what the business earns. Management says no significant new capex is needed for three years in biologics or albumin, and is still spending on API — a new oncology block due during FY27 and a solid-phase peptide plant management expects to commission by the end of it. The buying is a different animal: minority stakes in small biotechs — mAbTree, Alveolus Bio and most recently Gate2Brain — taken alongside contracts to be their manufacturing partner, a structure management called a unique strategy and declined to describe further. It sold Koanaa Healthcare Canada in January 2026 and 31% of the Sravathi joint venture in March. Capacity utilisation is not disclosed.
Improving, and the reason is volume rather than pricing. The EBITDA margin was 28.3% in FY26 against 24.9%, and the profit margin 15.9% against 6.1%. In the June quarter EBITDA margin held at 30% while gross margin fell from 76% to 71% — the CFO attributed that to raw material prices rising with the global political situation, passed on only partly. Holding the operating margin while the gross margin drops five points is what operating leverage looks like from the outside. One caveat sits underneath: licensing fees were 7% of FY26 revenue at ₹120 crore, down from ₹190 crore, and it carries far higher margins than the rest — though the CFO was clear that real development spending sits behind it, just in earlier years.
Better than it was, still short of its peers. Return on capital employed was 11.4% in FY26 against 6.9%, and return on equity 9.4% against 3.3%, on ₹3,251 crore of capital employed. Management computes 12.5% on its own basis for the trailing twelve months, and prefers a third number — an adjusted 18.3% on the same trailing basis, 17.4% for FY26, which is what the return becomes if you exclude the biologics and albumin plants that are built but not yet full. That is a fair thing to show and a poor thing to use, because shareholders own the whole balance sheet, not the finished half. India Ratings, working to its own definition, calculated 9.7%. For scale, Anthem Biosciences earns 29.6% and Neuland 26.6% on the same measure this site uses.
Yes on cash, slowly on collection. Operating cash flow was ₹342 crore in FY26 against ₹132 crore, and over three years the company has generated ₹611 crore of operating cash against ₹353 crore of reported profit — 1.7 times, which means the profit is being backed by money. Getting paid is the slower half: customers take 123 days, barely changed from 126, and inventory sits for 87 days. The full working capital cycle is 176 days, down from 197. Even after all that cash, free cash flow was still slightly negative in FY26, because the capex is not finished.
A founding family, in its second generation, running a group with a lot of parts. Vishnukant Bhutada, one of the founders in 1987, is Managing Director. Keshav Bhutada is Executive Director and CEO of Shilpa Pharma Lifesciences, the material subsidiary, and led the August earnings call; Madhav Bhutada, disclosed in the annual report as related to the Managing Director, runs Shilpa Biocare. All three are named as key management personnel of the group, though none of the six directors on Shilpa Medicare's own board is related to another. Omprakash Inani, of the promoter group, is Chairman — the chair is not independent, which is why SEBI requires half that board to be. It is: three of six. Alpesh Dalal is CFO. Underneath sits a group of roughly fourteen subsidiaries across the UK, Austria, the US, Spain, the UAE and Malaysia, three associates and two joint ventures. One subsidiary was merged into the parent and one sold during FY26.
The accounts are clean; the regulator is the problem. The statutory audit for FY26 carried no qualification, and neither did the secretarial audit. The auditor is B N P S and Associates LLP of Raichur, a local firm rather than one of the large national practices, appointed in 2022 for five years. In the standalone accounts, claims not acknowledged as debt jumped from ₹0.1 crore to ₹23.8 crore during FY26, while corporate guarantees given for subsidiaries fell from ₹491 crore to ₹141 crore. The regulatory record is where a reader should slow down. The US FDA has had an import alert on the Jadcherla formulation plant since February 2021 — five years — with three products specifically exempted from it. A re-inspection in November 2025 closed with eight Form 483 observations relating to data integrity, none of them repeats, and the Bengaluru site drew five procedural observations in May 2026. Shilpa is waiting on another inspection and is routing its new US launches through a third party in the meantime. Attrition assumed in the parent company's own gratuity valuation was 36.3%, up from 34.3%.
Shilpa is the smallest of the Indian contract manufacturers covered here, at ₹1,535 crore against Divi's ₹10,560 crore and Neuland's ₹2,023 crore. What it offers instead of scale is range under one roof — APIs, complex formulations, peptides, biologics, antibody-drug conjugates and fill-finish — sold to customers who want a single supplier for the whole chain. More than 20 CDMO customers have signed up to that proposition. Whether it pays is an FY28 question, not an FY27 one.
Everyone larger. Among the Indian contract manufacturers covered here, Divi's Laboratories turned over ₹10,560 crore in its last full year, Piramal Pharma ₹8,869 crore, Laurus Labs ₹6,813 crore, Gland Pharma ₹6,431 crore, Syngene ₹3,739 crore, Sai Life Sciences ₹2,192 crore, Anthem Biosciences ₹2,124 crore and Neuland Laboratories ₹2,023 crore. Shilpa is the smallest of them at ₹1,535 crore. In oncology APIs specifically the field is narrower, and in the combination Shilpa is selling — small molecules, large molecules, payloads, linkers, antibody-drug conjugates and fill-finish under one roof — management's claim is that few Indian companies offer all of it. That claim is about capability, not scale, and the scale gap is the part that shows up in the accounts.
Helping: a decade of spending that is finally arriving in the P&L. Eleven plants and R&D sites against five in FY20, more than ₹800 crore of R&D and ₹1,200 crore of capex across FY21 to FY26, and now launches landing — Nor-UDCA for fatty liver disease in India, three approved 505(b)(2) products, a Rotigotine patch cleared in Europe and filed in the US, and Aflibercept due in India this year with three marketing partners. Hurting: the US FDA import alert on Jadcherla, which matters more than the 5% of revenue the US produces, because almost every launch management is asking investors to look forward to lands there from FY28. Gross margin fell from 76% to 71% in the June quarter, which the CFO put down partly to raw material prices rising with the global political situation and only partly passed on to customers. Licensing income, which carries far higher margins than the rest, fell from ₹190 crore to ₹120 crore and is by management's own account not forecastable. And the CDMO business everyone is buying has one commercial product in it.
Durable demand, unreliable timing — and the timing is what decides any given year. Drug companies keep handing chemistry and manufacturing to outside partners, and that is not in question. What a contract manufacturer cannot control is when the money arrives, because the customer's trial calendar and launch date set it. Shilpa's own disclosure shows the shape: 25-plus programmes, three entering commercial supply in FY28, and management's answer on how many will mature is that it depends on our partner, because these programmes are not run by us. The money for the newer areas — biologics, antibody-drug conjugates, albumin — has already been spent, and management now says no significant further capex is needed there for three years, with what remains going to APIs and formulations. So the industry compounds and the company's revenue does not, at least not in a straight line.
It depends entirely on whether the plants fill. At ₹814.95 on 21 August 2026 Shilpa traded at 65.5 times FY26 earnings and 10.4 times sales, which is less than Anthem, Divi's or Neuland charge and more than Gland or Syngene — but with a return on capital of 11.4% against 29.6% at Anthem, 26.6% at Neuland and 21.5% at Divi's. The share has already doubled in a year, retail holders are up 25% and institutions have barely moved. Buying here is a bet that ₹884 crore of half-finished assets and 25 contract programmes turn into revenue on roughly the schedule management describes.
Sixty-five times earnings for a business earning 11% on its capital — the multiple is a forecast, not a verdict on what it has done. At ₹814.95 on 21 August 2026 Shilpa was worth ₹15,940 crore, at 6.2 times book and 10.4 times sales. On sales that is cheaper than Anthem Biosciences at 23.0, Divi's at 21.6, Neuland at 14.7, Laurus at 14.3 and Sai Life at 14.1, and dearer than Gland Pharma at 7.2 and Syngene at 4.4. The gap that explains most of it is the return: 11.4% on capital where Anthem earns 29.6% and Neuland 26.6%. You are paying a contract-manufacturer multiple for returns that are not yet contract-manufacturer returns, on the expectation that the plants fill up.
Small investors, mostly. The number of shareholders went from 48,636 to 60,926 in four quarters, a 25% increase, while institutions moved barely at all — 19.4% of the company against 18.7% a year earlier. Foreign institutions hold 11.4% and domestic ones 8.1%, and the domestic figure actually slipped from 8.6% last quarter. Mutual funds hold 4.2% across eleven schemes, one more than a quarter earlier. On a share that has doubled in a year, that is a retail crowd arriving and the professionals sitting still.
A few, and one departure worth noting. SBI Life Insurance is the largest institutional holder at 2.31% and has been adding — 39.7 lakh shares in March, 45.3 lakh in June. Cohesion MK Best Ideas holds 2.17%, Sunidhi Capital 2.25%, Dovetail India Fund 1.71%, Elm Park Fund 1.18%, Bandhan Healthcare Fund 1.24% and ICICI Prudential's ELSS scheme 1.17%, the last of these having cut its position by nearly half since December. Amal Parikh holds 1.73% and Abhishek Khaitan 1.01%. Akash Bhanshali, a well-followed individual investor, held 1.52% through December 2025 and has since fallen below the 1% disclosure line.
Neither raising nor returning much. The one capital action of the year was a one-for-one bonus issue in October 2025, which doubled the share count to 19.56 crore and put no money in or out — every holder owns twice as many shares of the same company. The dividend is ₹0.60 a share, 4.8% of profit, which on this price is a rounding error rather than a reason to own it. There has been no buyback and no dilution in the last twelve months; the 19.9% increase in shares over five years is largely the April 2024 issue of 1.1 crore shares. Capex is being funded from cash generated, not from shareholders.
Loading…